Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Antimicrobial and non-antimicrobial tetracyclines in human cancer trials.

Richards C, Pantanowitz L, Dezube BJ.

Pharmacol Res. 2011 Feb;63(2):151-6. doi: 10.1016/j.phrs.2010.10.008. Epub 2010 Oct 15. Review.

PMID:
20951804
2.

Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.

Lokeshwar BL.

Pharmacol Res. 2011 Feb;63(2):146-50. doi: 10.1016/j.phrs.2010.11.003. Epub 2010 Nov 18. Review.

3.

Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs.

Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR.

Crit Rev Oral Biol Med. 1991;2(3):297-321. Review.

4.

Tetracycline inhibition and the cellular source of collagenase in gingival crevicular fluid in different periodontal diseases. A review article.

Ingman T, Sorsa T, Suomalainen K, Halinen S, Lindy O, Lauhio A, Saari H, Konttinen YT, Golub LM.

J Periodontol. 1993 Feb;64(2):82-8. Review.

PMID:
8433257
5.

Introduction and background.

Golub LM.

Pharmacol Res. 2011 Feb;63(2):99-101. doi: 10.1016/j.phrs.2010.10.003. Epub 2010 Oct 16.

PMID:
20937387
6.

Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms.

Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T.

Adv Dent Res. 1998 Nov;12(2):12-26. Review.

PMID:
9972117
7.

The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.

Vernillo AT, Ramamurthy NS, Golub LM, Rifkin BR.

Curr Opin Periodontol. 1994:111-8. Review.

PMID:
8032451
8.

Host modulation with tetracyclines and their chemically modified analogues.

Golub LM, Suomalainen K, Sorsa T.

Curr Opin Dent. 1992 Mar;2:80-90. Review.

PMID:
1325849
9.

Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature.

Griffin MO, Fricovsky E, Ceballos G, Villarreal F.

Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. doi: 10.1152/ajpcell.00047.2010. Epub 2010 Jun 30. Review.

10.

Clinical applications of non-antimicrobial tetracyclines in dermatology.

Monk E, Shalita A, Siegel DM.

Pharmacol Res. 2011 Feb;63(2):130-45. doi: 10.1016/j.phrs.2010.10.007. Epub 2010 Oct 19. Review.

PMID:
20937386
11.

Treating periodontal diseases by blocking tissue-destructive enzymes.

Golub LM, Wolff M, Roberts S, Lee HM, Leung M, Payonk GS.

J Am Dent Assoc. 1994 Feb;125(2):163-9; discussion 169-71. Review.

PMID:
8113524
12.
13.

COL-3 benefits patients with AIDS-related Kaposi's sarcoma.

Furlow B.

Lancet Oncol. 2006 May;7(5):368. No abstract available.

PMID:
16696161
15.

Tetracyclines: nonantibiotic properties and their clinical implications.

Sapadin AN, Fleischmajer R.

J Am Acad Dermatol. 2006 Feb;54(2):258-65. Review.

PMID:
16443056
16.

Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases.

Sorsa T, Ramamurthy NS, Vernillo AT, Zhang X, Konttinen YT, Rifkin BR, Golub LM.

J Rheumatol. 1998 May;25(5):975-82.

PMID:
9598901
17.

Doxycycline and other tetracyclines in the treatment of bone metastasis.

Saikali Z, Singh G.

Anticancer Drugs. 2003 Nov;14(10):773-8. Review.

PMID:
14597870
18.

Tetracyclines in the management of periodontal diseases. A review.

Seymour RA, Heasman PA.

J Clin Periodontol. 1995 Jan;22(1):22-35. Review.

PMID:
7706536
19.

[Nonantimicrobial effects of tetracyclines].

GarcĂ­a-Alvarez L, Oteo JA.

Rev Esp Quimioter. 2010 Mar;23(1):4-11. Review. Spanish.

20.

CMT-3. CollaGenex.

Fingleton B.

Curr Opin Investig Drugs. 2003 Dec;4(12):1460-7. Review.

PMID:
14763133
Items per page

Supplemental Content

Write to the Help Desk